President Trump listens to FDA Commissioner Stephen Hahn speaking at a press briefing on the Covid-19 pandemic with members of the Coronavirus Task Force at the White House in Washington on March 19, 2020. Photo by Yuri Gripas/Abaca/Sipa USA(Sipa via AP Images)
March 20, 2020 06:44 AM EDTUpdated 08:30 AM
Coronavirus

Drug­mak­er re­thinks its de­ci­sion to dou­ble price of a gener­ic af­ter Trump calls it a coro­n­avirus life­saver — re­ports

Natalie Grover

Reporter

Af­ter Pres­i­dent Trump on Thurs­day im­plied a decades-old malar­ia drug was sanc­tioned by the FDA to fight the new coro­n­avirus, re­ports emerged that late last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times